La presencia de varices esofágicas (VE) es una de las complicaciones más frecuentes de la hipertensión portal en los pacientes cirróticos y puede complicarse en el 30% - 40% de los casos con episodios de sangrado gravados con una mortalidad del 15-20%. El diagnóstico precoz de las VE antes del primer episodio de sangrado es esencial, ya que...
-
March 13, 2018 (v1)PublicationUploaded on: December 4, 2022
-
September 10, 2024 (v1)Publication
Objectives: The course of progressive liver damage after achieving sustained virological response (SVR) with direct-acting antivirals (DAAs) remains undetermined. We aimed to determine risk factors associated with the development of liver-related events (LREs) after SVR, focusing on the utility of non-invasive markers. Methods: An...
Uploaded on: September 11, 2024 -
February 27, 2015 (v1)Publication
No description
Uploaded on: March 27, 2023 -
October 4, 2022 (v1)Publication
Introducción y objetivos: la pandemia por el SARS-CoV-2 ha obligado a un cambio sustancial en la atención a los pacien- tes con patologías digestivas, en especial a los pacientes con enfermedad inflamatoria intestinal (EII), por estar tra- tados con fármacos inmunomoduladores. En este sentido, algunas guías nacionales e internacionales han...
Uploaded on: March 24, 2023 -
February 27, 2015 (v1)Publication
No description
Uploaded on: December 4, 2022 -
April 27, 2021 (v1)Publication
Background: Several studies have reported positive efficacy outcomes for patients with inflammatory bowel disease treated with CT-P13, an infliximab biosimilar. Data from followup periods longer than 1 year are still scarce. Here, we assessed the long-term efficacy data, loss of response and safety after switching from infliximab to CT-P13 in...
Uploaded on: December 4, 2022 -
February 27, 2015 (v1)Publication
No description
Uploaded on: December 4, 2022 -
February 27, 2015 (v1)Publication
No description
Uploaded on: December 4, 2022 -
September 27, 2022 (v1)Publication
Introduction: patients with advanced chronic liver disease (CLD) may be at an increased risk of a severe course due to cirrhosis-associated immune dysfunction. The aim of this study was to determine the prevalence of CLD in COVID-19 patients and to analyze the course of the infection, compared with patients with non-liver disease. Materials and...
Uploaded on: March 24, 2023